NCT06149533View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

May 30, 2026

Study Completion Date

November 30, 2026

Conditions
Thrombosis, VenousCancerCatheter Complications
Interventions
DRUG

Edoxaban

Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.

Trial Locations (1)

100021

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER